Intended for licensed healthcare professionals located in Austria.
Summary of Product Characteristics – Austria
ICLUSIG
Home
View expert videos
on ICLUSIG
ICLUSIG
resources
ICLUSIG 10 Year - Because Tomorrows Matters Today
Blue square
Resources for ICLUSIG

Learn more about the treatment
for CML and Ph+ ALL

10 year logo
ICLUSIG has been with you since 2013. At this 10-year milestone, we celebrate the combined experience and data we’ve built with ICLUSIG that may improve patients’ futures.1,2
Video intro icon

ICLUSIG 10-year anniversary video

Play the video below to learn more about the key milestones of ICLUSIG and celebrate together the progress made over the past decade in the treatment of patients with CML and Ph+ ALL.

10-year icon

ICLUSIG 10-year INFOGRAPHIC

Want to discover more about the combined experience and data with ICLUSIG? Click the link below to download a concise and informative ICLUSIG infographic.

Download the ICLUSIG 10-year INFOGRAPHIC
Watch a series of short videos
where experts tell the ICLUSIG story
Click here

Abbreviations: CML, chronic myeloid leukaemia; Ph+ ALL, Philadelphia chromosome-positive acute lymphoblastic leukaemia.

References: 1. Cortes JE, et al. Blood. 2018;132:393–404; 2. Cortes J, et al. Blood. 2021;138:2042–50.

Privacy Policy Cookie Policy Terms of Use Imprint

Please refer to the product information of your home country for more information.

AT/ICLG/P/23/0014
Date of preparation: June 2023

© 2024, Incyte. All rights reserved.
Marketing authorisation holder: Incyte Biosciences Austria GmbH.
ICLUSIG, the ICLUSIG logo and the Incyte logo are registered trademarks of Incyte.

If you would like to request further medical information, please visit:
https://www.incyteglobalmedicalinformation.com/